Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development
Although tuberculosis remains a major global health problem, Bacille Calmette-Guérin (BCG) is the only available vaccine. However, BCG has limited applications, and a more effective vaccine is needed. Cellular mediated immunity (CMI) is thought to be the most important immune response for protection...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/527395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564415706169344 |
|---|---|
| author | Mamiko Niki Maho Suzukawa Shunsuke Akashi Hideaki Nagai Ken Ohta Manabu Inoue Makoto Niki Yukihiro Kaneko Kozo Morimoto Atsuyuki Kurashima Seigo Kitada Sohkichi Matsumoto Koichi Suzuki Yoshihiko Hoshino |
| author_facet | Mamiko Niki Maho Suzukawa Shunsuke Akashi Hideaki Nagai Ken Ohta Manabu Inoue Makoto Niki Yukihiro Kaneko Kozo Morimoto Atsuyuki Kurashima Seigo Kitada Sohkichi Matsumoto Koichi Suzuki Yoshihiko Hoshino |
| author_sort | Mamiko Niki |
| collection | DOAJ |
| description | Although tuberculosis remains a major global health problem, Bacille Calmette-Guérin (BCG) is the only available vaccine. However, BCG has limited applications, and a more effective vaccine is needed. Cellular mediated immunity (CMI) is thought to be the most important immune response for protection against Mycobacterium tuberculosis (Mtb). However, the recent failure of a clinical trial for a booster BCG vaccine and increasing evidence of antibody-mediated immunity prompted us to evaluate humoral immunity to Mtb-specific antigens. Using Enzyme-Linked ImmunoSpot and Enzyme-Linked ImmunoSorbent Assays, we observed less correlation of both CMI and IgG titers with patient clinical status, including serum concentration of C reactive protein. However, IgA titers against Mtb were significantly correlated with clinical status, suggesting that specific IgA antibodies protect against Mtb proliferation. In addition, in some cases, IgA antibody titers were significantly associated with the serum concentration of total albumin, which supports the idea that humoral immunity can be influenced by the nutritional status. Based on these observations, we propose that the induction of humoral immunity should be included as an option in TB vaccine development strategies. |
| format | Article |
| id | doaj-art-918916a58a4049a491e3580fdcbf77c2 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-918916a58a4049a491e3580fdcbf77c22025-02-03T01:11:02ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/527395527395Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine DevelopmentMamiko Niki0Maho Suzukawa1Shunsuke Akashi2Hideaki Nagai3Ken Ohta4Manabu Inoue5Makoto Niki6Yukihiro Kaneko7Kozo Morimoto8Atsuyuki Kurashima9Seigo Kitada10Sohkichi Matsumoto11Koichi Suzuki12Yoshihiko Hoshino13Department of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanNational Hospital Organization, National Tokyo Hospital, Takeoka, Kiyose, Tokyo 204-8585, JapanNational Hospital Organization, National Tokyo Hospital, Takeoka, Kiyose, Tokyo 204-8585, JapanNational Hospital Organization, National Tokyo Hospital, Takeoka, Kiyose, Tokyo 204-8585, JapanNational Hospital Organization, National Tokyo Hospital, Takeoka, Kiyose, Tokyo 204-8585, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanNational Hospital Organization, National Toneyama Hospital, Toneyama, Toyonaka, Osaka 560-8552, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashimurayama, Tokyo 189-0002, JapanDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashimurayama, Tokyo 189-0002, JapanAlthough tuberculosis remains a major global health problem, Bacille Calmette-Guérin (BCG) is the only available vaccine. However, BCG has limited applications, and a more effective vaccine is needed. Cellular mediated immunity (CMI) is thought to be the most important immune response for protection against Mycobacterium tuberculosis (Mtb). However, the recent failure of a clinical trial for a booster BCG vaccine and increasing evidence of antibody-mediated immunity prompted us to evaluate humoral immunity to Mtb-specific antigens. Using Enzyme-Linked ImmunoSpot and Enzyme-Linked ImmunoSorbent Assays, we observed less correlation of both CMI and IgG titers with patient clinical status, including serum concentration of C reactive protein. However, IgA titers against Mtb were significantly correlated with clinical status, suggesting that specific IgA antibodies protect against Mtb proliferation. In addition, in some cases, IgA antibody titers were significantly associated with the serum concentration of total albumin, which supports the idea that humoral immunity can be influenced by the nutritional status. Based on these observations, we propose that the induction of humoral immunity should be included as an option in TB vaccine development strategies.http://dx.doi.org/10.1155/2015/527395 |
| spellingShingle | Mamiko Niki Maho Suzukawa Shunsuke Akashi Hideaki Nagai Ken Ohta Manabu Inoue Makoto Niki Yukihiro Kaneko Kozo Morimoto Atsuyuki Kurashima Seigo Kitada Sohkichi Matsumoto Koichi Suzuki Yoshihiko Hoshino Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development Journal of Immunology Research |
| title | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development |
| title_full | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development |
| title_fullStr | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development |
| title_full_unstemmed | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development |
| title_short | Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development |
| title_sort | evaluation of humoral immunity to mycobacterium tuberculosis specific antigens for correlation with clinical status and effective vaccine development |
| url | http://dx.doi.org/10.1155/2015/527395 |
| work_keys_str_mv | AT mamikoniki evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT mahosuzukawa evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT shunsukeakashi evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT hideakinagai evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT kenohta evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT manabuinoue evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT makotoniki evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT yukihirokaneko evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT kozomorimoto evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT atsuyukikurashima evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT seigokitada evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT sohkichimatsumoto evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT koichisuzuki evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment AT yoshihikohoshino evaluationofhumoralimmunitytomycobacteriumtuberculosisspecificantigensforcorrelationwithclinicalstatusandeffectivevaccinedevelopment |